Injection of Ranibizumab Versus Combination of Ranibizumab and Triamcinolone Acetate for (CRVO)
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
To compare the clinical effectiveness of ranibizumab and combination of ranibizumab and
triamcinolone for the treatment of macular oedema secondary to CRVO